Dan Chalothorn

Title: The Innovative Contributions of Dan Chalothorn

Introduction

Dan Chalothorn is a prominent inventor based in New York, NY (US), known for his significant contributions to the field of biotechnology. With a total of 6 patents, Chalothorn has made remarkable advancements in the understanding and application of genetic modifications in non-human animals.

Latest Patents

Chalothorn's latest patents include a method of using a genetically modified mouse that expresses human albumin. This patent details non-human animal genomes, non-human animal cells, and non-human animals that comprise a humanized albumin locus. These innovations allow for the assessment of in vivo efficacy of human-albumin-targeting reagents, such as nuclease agents designed to target human albumin. Another notable patent involves Factor XI A2 domain-binding antibodies. This patent provides antibodies that bind to the A2 domain of Factor XI (FXI) and outlines methods for using these antibodies to inhibit blood clot formation without affecting hemostasis. These advancements have potential applications in treating blood clotting diseases and disorders.

Career Highlights

Throughout his career, Dan Chalothorn has worked with leading companies in the biotechnology sector, including Regeneron Pharmaceuticals, Inc. His work has been instrumental in developing innovative solutions that address critical health issues.

Collaborations

Chalothorn has collaborated with notable colleagues, including Lori C. Morton and KehDih Lai, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Dan Chalothorn's contributions to biotechnology through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in medical treatments and genetic research.